Allurion Technologies (ALUR) Small-Cap Growth Virtual Investor Conference summary

Market opportunity and industry trends

• Obesity is projected to be a $50–$100 billion revenue opportunity by 2030, with the U.S. alone representing an $18 billion annual market and 10 million potential adult patients if approved.

• The market is underpenetrated, with bariatric surgery reaching only 1% of eligible patients globally.

• GLP-1 drugs have driven awareness but face high churn rates and limited long-term adherence, creating demand for alternative solutions.

• Digital health platforms are increasingly important, offering remote monitoring and behavior change programs that complement both device and drug therapies.

Product innovation and differentiation

• The gastric balloon is procedureless, delivered in a 15-minute office visit, and requires no anesthesia or surgery.

• Achieves 14–15% total body weight loss in one cycle, over 20% with a second cycle, and maintains 96% of weight loss one year post-removal.

• Adverse event and intolerance rates are an order of magnitude lower than previous devices.

• The balloon is paired with an AI-powered digital platform and mobile app for remote monitoring, coaching, and behavior change.

Financial performance and business model

• 2023 revenue was $53 million with nearly 80% gross margin; procedural volumes grew 30% despite revenue decline due to macro headwinds and GLP-1 competition.

• Inventory destocking in Q4 2023 and Q1 2024; sequential revenue and procedural volume growth observed in Q1.

• Operating expenses and cash burn were significantly reduced, with a forecasted $30 million burn in 2024, down from $64 million in 2023.

• Digital platform revenue is currently small but expected to grow as adoption increases, especially in the U.S.